PTAB institutes Coherus' IPR challenge to Humira

Coherus BioSciences Inc. (NASDAQ:CHRS) gained $2.58 (16%) to $18.85 on Tuesday after the U.S. Patent Trial and Appeal Board instituted

Read the full 207 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE